Flag of the European Union EU Clinical Trials Register Help

Clinical Trials

The EU Clinical Trials Register website allows you to search for protocol and results information on interventional clinical trials which are conducted in the European Union (EU), the European Economic Area (EEA) and clinical trials which are conducted outside the EU/EEA if they form part of a paediatric investigation plan (PIP). Learn   more about the EU clinical trial register   including the source of the information and the legal basis.

The EU clinical trials register currently displays   x   clinical trials of which   y   are clinical trials conducted with subjects less than 18 years old.
 
Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]
Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
Advanced Search: Search tools
 
Print Download
Summary
EudraCT Number:2009-012988-34
Sponsor's Protocol Code Number:NI-0401-04
National Competent Authority:Austria - BASG
Clinical Trial Type:EEA CTA
Trial Status:Prematurely Ended
Date on which this record was first entered in the EudraCT database:2009-08-19
Trial results
Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL
Expand All   Collapse All
A. Protocol Information
A.1Member State ConcernedAustria - BASG
A.2EudraCT number2009-012988-34
A.3Full title of the trial
A multicenter, randomized, double-blind, placebo-controlled clinical trial investigating the safety and efficacy of NI-0401 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D)
A.4.1Sponsor's protocol code numberNI-0401-04
A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
A.8EMA Decision number of Paediatric Investigation Plan
B. Sponsor Information
B.Sponsor: 1
B.1.1Name of SponsorNovImmune SA
B.1.3.4CountrySwitzerland
B.3.1 and B.3.2Status of the sponsorCommercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1Name of organisation providing support
B.4.2Country
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1Name of organisation
B.5.2Functional name of contact point
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation No
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.2Product code NI-0401
D.3.4Pharmaceutical form Concentrate for solution for infusion
D.3.4.1Specific paediatric formulation Information not present in EudraCT
D.3.7Routes of administration for this IMPIntravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.9.2Current sponsor codeNI-0401
D.3.9.3Other descriptive nameFully human monoclonal antibody directed against the CD3 epsilon chain expressed on all T-cells
D.3.10 Strength
D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
D.3.10.2Concentration typeequal
D.3.10.3Concentration number2
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product Information not present in EudraCT
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product Yes
D.3.11.13.1Other medicinal product typeMonoclonal antibody
D.8 Information on Placebo
D.8 Placebo: 1
D.8.1Is a Placebo used in this Trial?Yes
D.8.3Pharmaceutical form of the placeboConcentrate for solution for infusion
D.8.4Route of administration of the placeboIntravenous use
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1Medical condition(s) being investigated
Preservation of beta (β)-islet cell function in patients newly diagnosed with Type 1 Diabetes
MedDRA Classification
E.1.2 Medical condition or disease under investigation
E.1.2Version 9.1
E.1.2Level LLT
E.1.2Classification code 10045228
E.1.2Term Type I diabetes mellitus
E.1.3Condition being studied is a rare disease No
E.2 Objective of the trial
E.2.1Main objective of the trial
To investigate the effect of NI-0401 on the preservation of β-islet cell function as demonstrated by the AUC of stimulated C-peptide release.
To investigate the safety of three dose regimens of NI-0401 in patients with newly diagnosed T1D.
E.2.2Secondary objectives of the trial
To investigate the effect of therapy with NI-0401 on the metabolic control of T1D demonstrated by regular measurement of: HbA1c over timeo; Insulin requirements over time; Average glucose measurements over time; Episodes of hyper and hypoglycemia.
To assess the pharmacodynamic and immunomodulatory effect of NI-0401 as demonstrated by regular measurement of: extent and duration of CD3-TCR modulation; number of circulating leucocytes and leucocyte subsets; serum pro and anti inflammatory cytokines; mRNA expression in leucocyteso plasma concentration of diabetes associated auto antibodies.
To assess the plasma pharmacokinetics of NI-0401.
To assess the potential for emergent anti-drug antibody and its effect on the efficacy and safety of NI-0401.
To assess the safety and efficacy of a single course vs. two courses of NI-0401 in patients with newly diagnosed T1D.
E.2.3Trial contains a sub-study No
E.3Principal inclusion criteria
1. Patients with T1D diagnosed according to the American Diabetes Association 2003 criteria
2. Date of diagnosis within 12 weeks prior to the first dose of study drug
3. Evidence of diabetes associated autoantibodies including at least one of the following: Glutamic acid decarboxylase 65 antibody (GADA); Protein tyrosine phosphatase-like protein IA-2 (IA-2A); Islet cell antibody (ICA)
4. Male or Female patients aged ≥ 12 and ≤ 40 years
5. Fasting C-peptide level ³ 0.25 nmol/l
6. Effective written informed consent
7. EBV-IgG antibody positive
8. Willing to avoid pregnancy during trial participation.
E.4Principal exclusion criteria
1. Pregnant or lactating women
2. Any medical condition that, in the opinion of the investigator, would interfere with safe completion of the trial or that would prevent patients from providing informed consent.
3. Known or previous diagnosis of malignancies.
4. Current active infections: Any current active infection; Active tuberculosis (TB) within 12 months of study entry or currently undergoingtreatment for TB; Evidence of active or chronic hepatitis including hepatitis B or C; History of or currently active primary or secondary immunodeficiency including known history of HIV infection; Patients with detectable EBV/CMV viral DNA in plasma.
5. Current active alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to baseline.
6. A history of hypersensitivity or allergy to any components of the study regimen.
7. Previous treatment with any cell-depleting therapies, including investigational agents (e.g. alemtuzumab, anti-CD3, anti-CD4, anti-CD5, anti-CD11a, anti-CD19, anti-CD22, anti-BLys/BAFF, or anti-CD20).
8. Treatment with another investigational drug within 3 months or five half-lives of the investigational drug prior to baseline, whichever is longer.
9. Receipt of or need for a live vaccine within 8 weeks prior to and following receipt of study drug treatment.
10. Laboratory tests; WBC count < 2500 x 106/l; CD4 lymphocyte count < 500 x 106/l; ALT > 2 ULN.
E.5 End points
E.5.1Primary end point(s)
The mean change from baseline in the AUC of stimulated C-Peptide at Month 6
E.6 and E.7 Scope of the trial
E.6Scope of the trial
E.6.1Diagnosis Information not present in EudraCT
E.6.2Prophylaxis Information not present in EudraCT
E.6.3Therapy Yes
E.6.4Safety Yes
E.6.5Efficacy Yes
E.6.6Pharmacokinetic Yes
E.6.7Pharmacodynamic Yes
E.6.8Bioequivalence Information not present in EudraCT
E.6.9Dose response Yes
E.6.10Pharmacogenetic Information not present in EudraCT
E.6.11Pharmacogenomic Information not present in EudraCT
E.6.12Pharmacoeconomic Information not present in EudraCT
E.6.13Others Information not present in EudraCT
E.7Trial type and phase
E.7.1Human pharmacology (Phase I) No
E.7.1.1First administration to humans No
E.7.1.2Bioequivalence study No
E.7.1.3Other No
E.7.1.3.1Other trial type description
E.7.2Therapeutic exploratory (Phase II) Yes
E.7.3Therapeutic confirmatory (Phase III) No
E.7.4Therapeutic use (Phase IV) No
E.8 Design of the trial
E.8.1Controlled Yes
E.8.1.1Randomised Yes
E.8.1.2Open No
E.8.1.3Single blind No
E.8.1.4Double blind Yes
E.8.1.5Parallel group Yes
E.8.1.6Cross over No
E.8.1.7Other No
E.8.2 Comparator of controlled trial
E.8.2.1Other medicinal product(s) No
E.8.2.2Placebo Yes
E.8.2.3Other No
E.8.3 The trial involves single site in the Member State concerned No
E.8.4 The trial involves multiple sites in the Member State concerned Yes
E.8.4.1Number of sites anticipated in Member State concerned4
E.8.5The trial involves multiple Member States Yes
E.8.5.1Number of sites anticipated in the EEA57
E.8.6 Trial involving sites outside the EEA
E.8.6.1Trial being conducted both within and outside the EEA Yes
E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
E.8.7Trial has a data monitoring committee Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
The point at which all patients have completed the month 24 visit (or prematurely discontinued) and the database is locked for the Month 24 analysis
E.8.9 Initial estimate of the duration of the trial
E.8.9.1In the Member State concerned years3
E.8.9.1In the Member State concerned months0
E.8.9.1In the Member State concerned days0
E.8.9.2In all countries concerned by the trial years3
E.8.9.2In all countries concerned by the trial months0
E.8.9.2In all countries concerned by the trial days0
F. Population of Trial Subjects
F.1 Age Range
F.1.1Trial has subjects under 18 Yes
F.1.1.1In Utero No
F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.3Newborns (0-27 days) No
F.1.1.4Infants and toddlers (28 days-23 months) No
F.1.1.5Children (2-11years) No
F.1.1.6Adolescents (12-17 years) Yes
F.1.2Adults (18-64 years) Yes
F.1.3Elderly (>=65 years) No
F.2 Gender
F.2.1Female Yes
F.2.2Male Yes
F.3 Group of trial subjects
F.3.1Healthy volunteers No
F.3.2Patients Yes
F.3.3Specific vulnerable populations Yes
F.3.3.1Women of childbearing potential not using contraception No
F.3.3.2Women of child-bearing potential using contraception Yes
F.3.3.3Pregnant women No
F.3.3.4Nursing women No
F.3.3.5Emergency situation No
F.3.3.6Subjects incapable of giving consent personally Yes
F.3.3.6.1Details of subjects incapable of giving consent
Adolescents (12 to 17 years of age)
F.3.3.7Others No
F.4 Planned number of subjects to be included
F.4.1In the member state13
F.4.2 For a multinational trial
F.4.2.1In the EEA 100
F.4.2.2In the whole clinical trial 160
G. Investigator Networks to be involved in the Trial
N. Review by the Competent Authority or Ethics Committee in the country concerned
N.Competent Authority Decision Authorised
N.Date of Competent Authority Decision2009-10-13
N.Ethics Committee Opinion of the trial applicationFavourable
N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
N.Date of Ethics Committee Opinion2009-09-10
P. End of Trial
P.End of Trial StatusPrematurely Ended
P.Date of the global end of the trial2009-10-26
EU Clinical Trials Register Service Desk: euctr@ema.europa.eu
European Medicines Agency © 1995-2014 | 7 Westferry Circus, Canary Wharf, London E14 4HB
Legal notice
EMA HMA